Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man.
Interactions between the hypothalamic-pituitary-adrenal (HPA) axis and central dopamine systems have been hypothesized to play a role in the pathophysiology of psychosis, but the normal physiology of HPA axis-dopamine interactions has not been fully defined. We report results from two uncontrolled pilot studies which explored the effects of ovine corticotropin-releasing hormone (CRH) on dopamine activity in healthy human subjects. Administration of CRH did not produce changes in plasma levels of homovanillic acid (HVA), the major dopamine metabolite, over the subsequent 3.5 hours. However, when the effects of CRH were followed over a longer period in a small subgroup, we found that CRH administration produced a two-fold rise in plasma HVA levels 20 hours later, without affecting plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), a major metabolite of norepinephrine. Thus, the findings of these pilot studies suggest that CRH may exert delayed but not acute effects on dopamine activity in man.
Massachusetts Mental Health Center.
J A
JA
Posener
J J
JJ
Schildkraut
G H
GH
Williams
R E
RE
Gleason
M S
MS
Salomon
G
G
Mecheri
A F
AF
Schatzberg
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000704:Analysis of Variance; D003346:Corticotropin-Releasing Hormone; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood; D008875:Middle Aged; D013997:Time Factors
D008734:Methoxyhydroxyphenylglycol; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D004298:Dopamine; D006854:Hydrocortisone